{"id":"W2165181124","doi":"10.1200/jco.2007.12.5807","title":"Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Immune Response and Inflammation","field":"Immunology and Microbiology","cited_by":169,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"McGill University; Pfizer Pharmaceuticals; American Society of Clinical Oncology; Pfizer","keywords":"Medicine; Taxane; Chemotherapy; Internal medicine; Neutropenia; Clinical endpoint; Lung cancer; Oncology; Phases of clinical research; Gastroenterology; Surgery; Cancer; Urology; Breast cancer; Randomized controlled trial","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004146063,0.0002523267,0.002701839,0.0002513238,0.0001813113,0.000005382371,0.0002853968,0.0006624674,0.0003095909],"category_scores_gemma":[0.001887768,0.0001843744,0.0006110835,0.0001778953,0.0004976434,0.0002016892,0.00004206723,0.0007132399,0.000004482183],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002069843,"about_ca_system_score_gemma":0.002029791,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007387407,"about_ca_topic_score_gemma":0.0002127403,"domain_scores_codex":[0.9947817,0.0009659604,0.003550912,0.0002514512,0.0001076995,0.0003422302],"domain_scores_gemma":[0.9899696,0.004865504,0.004372136,0.0002130881,0.0005215998,0.00005810887],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9545649,0.004244993,0.0001295248,0.00007623388,0.0005677472,0.00002843596,0.000858193,0.0005828069,0.01923389,0.00005188864,0.002342948,0.01731838],"study_design_scores_gemma":[0.9024838,0.02798392,0.0001285472,0.0001720214,0.0002374244,0.00005093768,0.0001111009,0.0005709468,0.026193,0.00002908537,0.04184314,0.0001960834],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9887626,0.001213776,0.002752536,0.002687651,0.002256429,0.002020833,0.0000212802,0.00001112188,0.0002737919],"genre_scores_gemma":[0.9848348,0.00759289,0.002409691,0.0004651333,0.0003020187,0.0001658013,0.00005817168,0.00003624541,0.004135185],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05208116,"threshold_uncertainty_score":0.7518569,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0432886893044225,"score_gpt":0.382074831658081,"score_spread":0.3387861423536585,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}